Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants

2 de julio de 2026 actualizado por: Chiesi Farmaceutici S.p.A.

An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.

This Phase 1 study evaluates the effect of pantoprazole (a proton pump inhibitor) on the pharmacokinetics (PK) of CHF10196 (Florensocatib) in healthy male participants. Participants receive CHF10196 alone and in combination with pantoprazole to assess potential drug-drug interaction (DDI) effects on systemic exposure.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

18

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Leeds, Reino Unido
        • Fortrea Clinical Research Unit (CRU) Limited
        • Contacto:
          • Firas Almezedi

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Key Inclusion Criteria:

  • BMI (body mass index) between 18.0 and 30.0 kg/m²
  • Weight between 45 and 100 kg
  • Non-smokers or ex-smokers (<5 pack-years)
  • Clinically healthy based on medical history and examination
  • Normal vital signs
  • Normal ECG
  • Willingness to comply with contraception requirements

Key Exclusion Criteria:

  • Recent participation in another clinical study
  • Significant medical conditions
  • Abnormal laboratory values
  • Positive HIV or hepatitis tests
  • Recent infection or COVID-19
  • Drug or alcohol abuse
  • Use of prohibited medications
  • Gastrointestinal surgery affecting absorption
  • Hypersensitivity to study drugs

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196

Treatment Period 1:

CHF10196 single dose administration on Day1;

Treatment Period 2:

CHF10196 single dose administration after pantoprazole single dose administration on Day13

Treatment Period 2:

Pantoprazole single dose administration from Day8 to Day13

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
PK parameter: AUC0-∞
Periodo de tiempo: pre-dose up to 168 hours post-dose
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
pre-dose up to 168 hours post-dose
PK parameter: AUC0-t
Periodo de tiempo: pre-dose up to 168 hours post-dose
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
pre-dose up to 168 hours post-dose
PK parameter: Cmax
Periodo de tiempo: pre-dose up to 168 hours post-dose
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
pre-dose up to 168 hours post-dose

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and tolerability: Incidence of adverse events (AE)
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Safety and tolerability: Change from baselines for vital signs: PR
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP).

Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baselines for vital signs - RR
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP).

Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baselines for vital signs - blood pressure
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP).

Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baselines for ECG
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval

Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baseline for ECG (HR)
Periodo de tiempo: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

change from baseline for ECG recording of heart rate (HR)

Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196).

Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
Safety and tolerability: Change from baseline for laboratory abnormalities
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Number of participants with abnormal blood laboratory test results. Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: AUC0-24h
Periodo de tiempo: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
Additional pharmacokinetic parameters: CL/F
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: t1/2
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: Vd/F
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Additional pharmacokinetic parameters: tmax
Periodo de tiempo: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

14 de octubre de 2026

Finalización primaria (Estimado)

9 de diciembre de 2026

Finalización del estudio (Estimado)

9 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

26 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de julio de 2026

Publicado por primera vez (Actual)

6 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir